| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/09/2006 | US20060052379 Pyridazin-3(2h)-one derivatives as pde4 inhibitors |
| 03/09/2006 | US20060052378 Psychological disorders; analgesics; eating disorders; drug abuse; 4-(8-chloro-naphthalen-2-yl)-2-methyl-1,2,3,4-tetrahydroisoquinolin-7-ol; 7-(6-methoxy-pyrazin-2yl)-2-methyl-4-(naphthalene-2-yl)-1,2,3,4-tetrahydroisoquinoline; treating amide intermediates with sodium borohydride |
| 03/09/2006 | US20060052377 2-(Alpha-phenylthiobenzyl)morpholine derivatives, e.g., (4-fluorophenyl){[2-methoxyphenyl]thio}methyl)morpholine; serotonin and norepinephrine reuptake inhibitors |
| 03/09/2006 | US20060052376 Carboxamides |
| 03/09/2006 | US20060052375 Bis-alkylbenzylamines |
| 03/09/2006 | US20060052374 Amino-tetrazole analogues and methods of use |
| 03/09/2006 | US20060052373 Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides |
| 03/09/2006 | US20060052372 N-(Heterocycloalkyl)alkylsulfonamides, e.g., N-[3-[4-(3-Chlorophenyl)piperazin-1-yl]propyl]-N-(4-methoxyphenyl)-propanesulfonamide; improve blood flow to the optic nerve head and the retina ; used to treat retinal diseases, sleep disorders, depression, schizophrenia, anxiety, OCD, etc. |
| 03/09/2006 | US20060052371 2-(3-cyanophenyl)-4H-1,3-benzothiazin-4-one; cardiovascular, bone or joint diseases, infectious, inflammatory, kidney diseases; safe and good effects of cell death inhibition, Migration Inhibitory Factor (MIF) binding |
| 03/09/2006 | US20060052370 Methods and compositions for treating nociceptive pain |
| 03/09/2006 | US20060052369 Compositions and methods relating to novel compounds and targets thereof |
| 03/09/2006 | US20060052368 Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists |
| 03/09/2006 | US20060052367 Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker |
| 03/09/2006 | US20060052365 Protease inhibitors |
| 03/09/2006 | US20060052364 Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
| 03/09/2006 | US20060052363 which are incapable of metabolizing to BCPP+ like species, and have affinity for D2 receptor subtype and functions as dopamine receptor antagonist |
| 03/09/2006 | US20060052362 Skeletal muscle protecting agent |
| 03/09/2006 | US20060052361 Aids therapy; side effect reduction |
| 03/09/2006 | US20060052360 Compounds, compositions and methods |
| 03/09/2006 | US20060052359 Microbiocides; bactericides |
| 03/09/2006 | US20060052358 Modulators of ATP-binding cassette transporters |
| 03/09/2006 | US20060052357 Organometallic anti-tumour agent |
| 03/09/2006 | US20060052356 Pharmacological methods to modulate oxygen consumption |
| 03/09/2006 | US20060052354 Methods for treating migraine |
| 03/09/2006 | US20060052353 Topical dermatological formulations and use thereof |
| 03/09/2006 | US20060052352 Mixtures or organic compounds for the treatment of airway diseases |
| 03/09/2006 | US20060052351 Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of blood cholestrol and triglycerides and oxidative stress |
| 03/09/2006 | US20060052350 Crystalline forms of 1,24(S)-dihydroxy vitamin D2 |
| 03/09/2006 | US20060052349 Pyrrolo-naphthyl acids and methods for using them |
| 03/09/2006 | US20060052348 such as ({6-[2-(2-naphthylmethyl)-1,3-oxazol-5-yl]-2-naphthyl}oxy)acetic acid, used to modulate plasminogen activator inhibitor (PAI-1) gene expression and to treat PAI-1 related disorders; cardiovascular and respiratory disorders; fibrosis, polycystic ovary syndrome, Alzheimer's disease, or cancer |
| 03/09/2006 | US20060052347 Geranylgeranyl pyrophosphate synthase inhibitors |
| 03/09/2006 | US20060052346 Nucleoside phosphonate derivatives useful in the treatment of HIV infections |
| 03/09/2006 | US20060052345 Quinazolinone compounds as calcilytics |
| 03/09/2006 | US20060052344 Heterocyclic silicon compounds and their use in the treatment of diseases or conditions associated with gnrh (gonadotropin-releasing hormone) |
| 03/09/2006 | US20060052342 Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups |
| 03/09/2006 | US20060052341 Control of a biological function |
| 03/09/2006 | US20060052340 Ophthalmic solution |
| 03/09/2006 | US20060052339 N-acyl modified polysaccharides and pharmaceutical compositions comprising same and dietary calcium |
| 03/09/2006 | US20060052338 N-Acyl and quaternary ammonium modified polysaccharide fibers |
| 03/09/2006 | US20060052337 Polysaccharide and composition from Antrodia camphorata and use thereof |
| 03/09/2006 | US20060052336 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 03/09/2006 | US20060052335 Chondroitin synthetase and dna encoding the enzyme |
| 03/09/2006 | US20060052334 Sequential therapy comprising a 20(S)-camptothecian and a pyrimidine base analog |
| 03/09/2006 | US20060052333 Method of treating arrhythmias |
| 03/09/2006 | US20060052332 1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-carboxamides; adenosine receptors (A2A); for stimulating mammalian coronary vasodilatation for therapy and imaging the heart |
| 03/09/2006 | US20060052331 2-Substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity |
| 03/09/2006 | US20060052330 Using a adenosine compound for therapy of tachycardia, angina, myocardial infraction, cardiovascular disorders |
| 03/09/2006 | US20060052329 Regulation of human P2Y1-like G protein-coupled receptor |
| 03/09/2006 | US20060052326 Werner's syndrome helicase as a target for anti -HIV/AIDS therapy |
| 03/09/2006 | US20060052323 Method to inhibit cell growth using oligonucleotides |
| 03/09/2006 | US20060052319 Sensitization of cells to cytotoxic agents using oligonucleotides directed to nucleotide excision repair or transcritpion coupled repair genes |
| 03/09/2006 | US20060052318 Tyrosinase activity cntrolling agent, process for producing the same and external preparations containing the same |
| 03/09/2006 | US20060052317 Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis |
| 03/09/2006 | US20060052316 alpha -galactosylceramide; glycolipids; modulate NK T cells; autoimmune disease, cancer |
| 03/09/2006 | US20060052315 Cb 1/cb 2 receptor ligands and their use in the treatment of pain |
| 03/09/2006 | US20060052314 Pharmaceutical combination |
| 03/09/2006 | US20060052312 Paclitaxel hybrid derivatives |
| 03/09/2006 | US20060052310 Regulation of substrate activity |
| 03/09/2006 | US20060052309 Use of convertase inhibitors in the treatment of fibrosis and scarring |
| 03/09/2006 | US20060052308 Transglutaminase inhibitors and methods of use thereof |
| 03/09/2006 | US20060052306 GRAS composition for enhanced mucosal delivery of parathyroid hormone |
| 03/09/2006 | US20060052305 Method of treating osteoporosis using intranasal parathyroid hormone |
| 03/09/2006 | US20060052298 Use of stable glutamine derivatives to improve drug absorption |
| 03/09/2006 | US20060052297 Method of up-regulating tumor antigen expression using thymalfasin |
| 03/09/2006 | US20060052279 For electrophoretic or chromatographic analysis; uniform coupling without overstaining; proteins in a biological sample that is sought to be analyzed by an electrophoretic or chromatographic procedure are coupled to a dye in efficient manner by combining sample with solid dye, buffer, denaturing agent |
| 03/09/2006 | US20060052278 Diagnosis and treatment of human dormancy-related sequellae |
| 03/09/2006 | US20060051867 Cell growth |
| 03/09/2006 | US20060051842 Nucleic acid encoding alpha chain of human IL-11 receptor |
| 03/09/2006 | US20060051754 Transporter selectively transporting sulfate conjugate and its gene |
| 03/09/2006 | US20060051732 Blood substitutes; basic alpha keratose produced via ion exchange chromatography, and gamma keratose solubilized in an electrolyte solution; given pH, osmolarity, viscosity; shelf-life |
| 03/09/2006 | US20060051440 Factors that bind intestinal toxins |
| 03/09/2006 | US20060051439 comprises acerola seed extract containing quercitrin |
| 03/09/2006 | US20060051438 Herbal medicaments for the treatment of neurocerebrovascular disorders |
| 03/09/2006 | US20060051436 Composition for controlling excessive calorie intake-induced disorder, food product for controlling excessive calorie intake-induced disorder, skin preparation for external use for controlling excessive calorie intake-induced disorder, and controlling agent for excessive calorie intake-induced disorder |
| 03/09/2006 | US20060051433 Composition for accelerating secretion of estrogen and regenerating tissue cells of female sexual organs |
| 03/09/2006 | US20060051432 Topical medicament |
| 03/09/2006 | US20060051430 Silver dihydrogen citrate compositions |
| 03/09/2006 | US20060051429 Pharmaceutical compositions and methods for managing skin conditions |
| 03/09/2006 | US20060051426 Nanoparticles containing polymeric nucleic acid homologs pharmaceutical composition and articles of manufacture containing same and methods of use thereof |
| 03/09/2006 | US20060051425 Method of microencapsulation |
| 03/09/2006 | US20060051422 Stabilised solid drug dispersions in an organic carrier and a process for preparing the same |
| 03/09/2006 | US20060051421 Stable pharmaceutical formulations of benzimidazole compounds |
| 03/09/2006 | US20060051420 Pharmaceutical tablets containing tibolone and a coating |
| 03/09/2006 | US20060051419 Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 03/09/2006 | US20060051418 Pharmaceutical formulations of potassium ATP channel openers and uses thereof |
| 03/09/2006 | US20060051417 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| 03/09/2006 | US20060051416 Modified release formulations of memantine oral dosage forms |
| 03/09/2006 | US20060051414 Fast water-dispersible domperidone tablets |
| 03/09/2006 | US20060051413 Administering drug (propranolol, scopolamine, estradiol) across mucosal membrane at a pH of pH=-log(Ka*SiSu): Ka = ionization constant (dissociation constant) of the compound in water, Si = solubility of the ionized form, and Su = solubility of the non-ionized form; sublingual; cardiovascular disorders |
| 03/09/2006 | US20060051411 Antibacterial medicinal composition of enhanced oral absorptivity |
| 03/09/2006 | US20060051410 Pharmaceutical composition containing 2,2-dichloro-12-(4-chlorophenyl)-dodecanoic acid |
| 03/09/2006 | US20060051408 Microcapsules for stabilization of cosmetic, pharmaceutical or food products |
| 03/09/2006 | US20060051407 Method of treating ischemia-reperfusion injury |
| 03/09/2006 | US20060051406 Formulation of insoluble small molecule therapeutics in lipid-based carriers |
| 03/09/2006 | US20060051394 Biodegradable polyurethane and polyurethane ureas |
| 03/09/2006 | US20060051385 Cationic antiseptic compositions and methods of use |
| 03/09/2006 | US20060051378 Mucosal vaccines with chitosan adjuvant and meningococcal antigens |
| 03/09/2006 | US20060051374 Compositions and methods for mucosal vaccination |
| 03/09/2006 | US20060051373 Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods |
| 03/09/2006 | US20060051360 Non-denatured, recombinant human immunodeficiency virus (HIV) Tat that is free of bacterial RNA and endotoxin; |